As in previous studies, the SHIELD study found health care workers who received the Novavax vaccine reported significantly ...

Novavax (NVAX) closed the most recent trading day at $6.39, moving -0.31% from the previous trading session. This move lagged the S&P 500's daily loss of 0.17%. Meanwhile, the Dow experienced a drop ...

Novavax (NVAX) announced preliminary results from the SHIELD-Utah study that showed Novavax’s COVID-19 Vaccine, Adjuvanted 2024-2025 Formula ...

An advisory panel on vaccines meets, carefully, in the shadow of a health secretary who has often criticized it.

Sanofi’s next-generation experimental asthma drug failed to significantly reduce flare-ups in patients with ...

Duck Creek Technologies, the global intelligent solutions provider defining the future of property and casualty (P&C) and general insurance, has announced the appointment of General Daniel Hokanson, ...

Vaccine makers targeting COVID-19 to measles will come under investor scrutiny on Tuesday as a group of independent experts at the CDC are scheduled to meet for the first time to review U.S.

BNP Paribas Exane initiated coverage of Sanofi (SNY) with an Outperform rating and $65 price target Stay Ahead of the Market: Discover ...

by Timothy McQuiston, Vermont Business Magazine The Vermont Department of Health reported last week that the number of COVID-19 hospitalizations remains low, at under 5 after a spike in January.